Topical glaucoma medications - Possible implications on the meibomian glands.
dry eye disease
glaucoma
meibography
meibomian gland dysfunction
ocular surface
topical medications
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
01 Jun 2024
01 Jun 2024
Historique:
received:
14
02
2024
accepted:
21
05
2024
medline:
1
6
2024
pubmed:
1
6
2024
entrez:
1
6
2024
Statut:
aheadofprint
Résumé
One of the most common causes of blindness on a global scale is glaucoma. There is a strong association between glaucoma and increased intraocular pressure (IOP). Because of this, adequate IOP-lowering is the most important treatment strategy, mostly through topical eyedrops. Well-functioning meibomian glands are paramount for maintaining a stable tear film, and their dysfunction is the most common cause of dry eye disease. There is a growing concern that both topical glaucoma medications themselves and their added preservatives damage the meibomian glands, and consequently, the ocular surface. Preserved topical glaucoma medications appear to cause dysfunction and atrophy of the meibomian glands. Upon comparison, preserved formulations caused more symptoms of dry eye, tear film instability, inflammatory changes and meibomian gland dropout than the preservative-free counterpart. However, although seemingly less detrimental, unpreserved alternatives may diminish glandular efficacy, and, depending on the active ingredient, lead to glandular death. This negatively impacts quality of life, adherence to treatment regimens and prognosis. In this review, we explore the available evidence regarding the effects of IOP-lowering eye drops on the meibomian glands.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.
Références
Agnifili, L., Brescia, L., Oddone, F., Sacchi, M., D'Ugo, E., Di Marzio, G. et al. (2019) The ocular surface after successful glaucoma filtration surgery: a clinical, in vivo confocal microscopy, and immune‐cytology study. Scientific Reports, 9, 11299.
Agnifili, L., Fasanella, V., Costagliola, C., Ciabattoni, C., Mastropasqua, R., Frezzotti, P. et al. (2013) In vivo confocal microscopy of meibomian glands in glaucoma. The British Journal of Ophthalmology, 97, 343–349.
Agnifili, L., Figus, M., Sacchi, M., Oddone, F., Villani, E., Ferrari, G. et al. (2023) Managing the ocular surface after glaucoma filtration surgery: an orphan topic. Graefe's Archive for Clinical and Experimental Ophthalmology Online ahead of print.
Agnifili, L., Mastropasqua, R., Fasanella, V., Brescia, L., Scatena, B., Oddone, F. et al. (2018) Meibomian gland features and conjunctival goblet cell density in glaucomatous patients controlled with prostaglandin/timolol fixed combinations: a case control, cross‐sectional study. Journal of Glaucoma, 27, 364–370.
Agnifili, L., Sacchi, M., Figus, M., Posarelli, C., Lizzio, R.A.U., Nucci, P. et al. (2022) Preparing the ocular surface for glaucoma filtration surgery: an unmet clinical need. Acta Ophthalmologica, 100, 740–751.
Akpek, E.K., Amescua, G., Farid, M., Garcia‐Ferrer, F.J., Lin, A., Rhee, M.K. et al. (2019) Dry eye syndrome preferred practice pattern®. Ophthalmology, 126, P286–P334.
Arita, R., Itoh, K., Inoue, K. & Amano, S. (2008) Noncontact infrared meibography to document age‐related changes of the meibomian glands in a normal population. Ophthalmology, 115, 911–915.
Arita, R., Itoh, K., Maeda, S., Maeda, K., Furuta, A., Tomidokoro, A. et al. (2012a) Comparison of the long‐term effects of various topical antiglaucoma medications on meibomian glands. Cornea, 31, 1229–1234.
Arita, R., Itoh, K., Maeda, S., Maeda, K., Furuta, A., Tomidokoro, A. et al. (2012b) Effects of long‐term topical anti‐glaucoma medications on meibomian glands. Graefe's Archive for Clinical and Experimental Ophthalmology, 250, 1181–1185.
Baudouin, C., Garcher, C., Haouat, N., Bron, A. & Gastaud, P. (1994) Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology, 101, 454–460.
Baudouin, C., Labbe, A., Liang, H., Pauly, A. & Brignole‐Baudouin, F. (2010) Preservatives in eyedrops: the good, the bad and the ugly. Progress in Retinal and Eye Research, 29, 312–334.
Brandt, J.D., Wittpenn, J.R., Katz, L.J., Steinmann, W.N. & Spaeth, G.L. (1991) Conjunctival impression cytology in patients with glaucoma using long‐term topical medication. American Journal of Ophthalmology, 112, 297–301.
Broadway, D.C., Grierson, I., O'Brien, C. & Hitchings, R.A. (1994) Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Archives of Ophthalmology, 112, 1437–1445.
Bron, A.J., de Paiva, C.S., Chauhan, S.K., Bonini, S., Gabison, E.E., Jain, S. et al. (2017) TFOS DEWS II pathophysiology report. The Ocular Surface, 15, 438–510.
Cho, W.H., Lai, I.C., Fang, P.C., Chien, C.C., Tseng, S.L., Lai, Y.H. et al. (2018) Meibomian gland performance in glaucomatous patients with long‐term instillation of IOP‐lowering medications. Journal of Glaucoma, 27, 176–183.
Craig, J.P., Nichols, K.K., Akpek, E.K., Caffery, B., Dua, H.S., Joo, C.K. et al. (2017) TFOS DEWS II definition and classification report. The Ocular Surface, 15, 276–283.
Cunniffe, M.G., Medel‐Jimenez, R. & Gonzalez‐Candial, M. (2011) Topical antiglaucoma treatment with prostaglandin analogues may precipitate meibomian gland disease. Ophthalmic Plastic & Reconstructive Surgery, 27, e128–e129.
Fineide, F., Lagali, N., Adil, M.Y., Arita, R., Kolko, M., Vehof, J. et al. (2022) Topical glaucoma medications – clinical implications for the ocular surface. The Ocular Surface, 26, 19–49.
Gazzard, G., Konstantakopoulou, E., Garway‐Heath, D., Adeleke, M., Vickerstaff, V., Ambler, G. et al. (2023) Laser in glaucoma and ocular hypertension (LiGHT) trial: six‐year results of primary selective laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension. Ophthalmology, 130, 139–151.
Georgiev, G.A., Yokoi, N., Ivanova, S., Krastev, R. & Lalchev, Z. (2012) Surface chemistry study of the interactions of pharmaceutical ingredients with human meibum films. Investigative Ophthalmology & Visual Science, 53, 4605–4615.
Glaucoma EGSTaGf. (2021) European glaucoma society terminology and guidelines for glaucoma, 5th edition. The British Journal of Ophthalmology, 105, 1–169.
Guarnieri, A., Carnero, E., Bleau, A.M., Alfonso‐Bartolozzi, B. & Moreno‐Montanes, J. (2020) Relationship between OSDI questionnaire and ocular surface changes in glaucomatous patients. International Ophthalmology, 40, 741–751.
Guo, Y., Ha, J.Y., Piao, H.L., Sung, M.S. & Park, S.W. (2020) The protective effect of 3% diquafosol on meibomian gland morphology in glaucoma patients treated with prostaglandin analogs: a 12‐month follow‐up study. BMC Ophthalmology, 20, 277.
Ha, J.Y., Sung, M.S. & Park, S.W. (2019) Effects of preservative on the meibomian gland in glaucoma patients treated with prostaglandin analogues. Chonnam Medical Journal, 55, 156–162.
Han, X., Liu, Y., Kam, W.R. & Sullivan, D.A. (2018) Effect of brimonidine, an alpha2 adrenergic agonist, on human meibomian gland epithelial cells. Experimental Eye Research, 170, 20–28.
Han, X., Yang, S., Kam, W.R., Sullivan, D.A. & Liu, Y. (2020) The carbonic anhydrase inhibitor dorzolamide stimulates the differentiation of human meibomian gland epithelial cells. Current Eye Research, 45, 1604–1610.
Jaenen, N., Baudouin, C., Pouliquen, P., Manni, G., Figueiredo, A. & Zeyen, T. (2007) Ocular symptoms and signs with preserved and preservative‐free glaucoma medications. European Journal of Ophthalmology, 17, 341–349.
Jiang, X.Y., Yang, P.S., Xiao, O., Yu, K., Wang, S.Y., Yang, S.J. et al. (2022) Effects of PPAR‐gamma and RXR‐alpha on mouse meibomian gland epithelial cells during inflammation induced by latanoprost. Experimental Eye Research, 224, 109251.
Kam, W.R., Liu, Y., Ding, J. & Sullivan, D.A. (2016) Do cyclosporine a, an IL‐1 receptor antagonist, uridine triphosphate, Rebamipide, and/or Bimatoprost regulate human meibomian gland epithelial cells? Investigative Ophthalmology & Visual Science, 57, 4287–4294.
Kam, W.R. & Sullivan, D.A. (2011) Neurotransmitter influence on human meibomian gland epithelial cells. Investigative Ophthalmology & Visual Science, 52, 8543–8548.
Kim, J.H., Shin, Y.U., Seong, M., Cho, H.Y. & Kang, M.H. (2018) Eyelid changes related to meibomian gland dysfunction in early middle‐aged patients using topical glaucoma medications. Cornea, 37, 421–425.
Knop, E., Knop, N., Millar, T., Obata, H. & Sullivan, D.A. (2011) The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Investigative Ophthalmology & Visual Science, 52, 1938–1978.
Kolko, M., Gazzard, G., Baudouin, C., Beier, S., Brignole‐Baudouin, F., Cvenkel, B. et al. (2023) Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment. Ocul Surf, 29, 456–468.
Lee, S.Y., Lee, K., Park, C.K., Kim, S., Bae, H.W., Seong, G.J. et al. (2019) Meibomian gland dropout rate as a method to assess meibomian gland morphologic changes during use of preservative‐containing or preservative‐free topical prostaglandin analogues. PLoS One, 14, e0218886.
Lee, T.H., Sung, M.S., Heo, H. & Park, S.W. (2018) Association between meibomian gland dysfunction and compliance of topical prostaglandin analogs in patients with normal tension glaucoma. PLoS One, 13, e0191398.
Lemp, M.A., Crews, L.A., Bron, A.J., Foulks, G.N. & Sullivan, B.D. (2012) Distribution of aqueous‐deficient and evaporative dry eye in a clinic‐based patient cohort: a retrospective study. Cornea, 31, 472–478.
McCulley, J.P. & Shine, W. (1997) A compositional based model for the tear film lipid layer. Transactions of the American Ophthalmological Society, 95, 79–88; discussion 88‐93.
McKinnon, S.J., Goldberg, L.D., Peeples, P., Walt, J.G. & Bramley, T.J. (2008) Current management of glaucoma and the need for complete therapy. The American Journal of Managed Care, 14, S20–S27.
Milla, E., Stirbu, O., Rey, A., Duch, S., Buchacra, O., Robles, A. et al. (2012) Spanish multicenter tafluprost tolerability study. The British Journal of Ophthalmology, 96, 826–831.
Mocan, M.C., Uzunosmanoglu, E., Kocabeyoglu, S., Karakaya, J. & Irkec, M. (2016) The association of chronic topical prostaglandin analog use with meibomian gland dysfunction. Journal of Glaucoma, 25, 770–774.
Morthen, M.K., Magno, M.S., Utheim, T.P., Hammond, C.J. & Vehof, J. (2023) The work‐related burden of dry eye. The Ocular Surface, 28, 30–36.
Morthen, M.K., Magno, M.S., Utheim, T.P., Snieder, H., Hammond, C.J. & Vehof, J. (2021) The physical and mental burden of dry eye disease: a large population‐based study investigating the relationship with health‐related quality of life and its determinants. The Ocular Surface, 21, 107–117.
Morthen, M.K., Magno, M.S., Utheim, T.P., Snieder, H., Jansonius, N., Hammond, C.J. et al. (2022) The vision‐related burden of dry eye. The Ocular Surface, 23, 207–215.
Negri, L., Ferreras, A. & Iester, M. (2019) Timolol 0.1% in glaucomatous patients: efficacy, tolerance, and quality of life. Journal of Ophthalmology, 2019, 4146124.
Pflugfelder, S.C. & Baudouin, C. (2011) Challenges in the clinical measurement of ocular surface disease in glaucoma patients. Clinical Ophthalmology, 5, 1575–1583.
Portela, R.C., Fares, N.T., Machado, L.F., Sao Leao, A.F., de Freitas, D., Paranhos, A., Jr. et al. (2018) Evaluation of ocular surface disease in patients with glaucoma: clinical parameters, self‐report assessment, and Keratograph analysis. Journal of Glaucoma, 27, 794–801.
Pult, H. & Riede‐Pult, B. (2013) Comparison of subjective grading and objective assessment in meibography. Contact Lens & Anterior eye, 36, 22–27.
Rabensteiner, D.F., Aminfar, H., Boldin, I., Schwantzer, G. & Horwath‐Winter, J. (2018) The prevalence of meibomian gland dysfunction, tear film and ocular surface parameters in an Austrian dry eye clinic population. Acta Ophthalmologica, 96, e707–e711.
Rath, A., Eichhorn, M., Trager, K., Paulsen, F. & Hampel, U. (2019) In vitro effects of benzalkonium chloride and prostaglandins on human meibomian gland epithelial cells. Annals of Anatomy, 222, 129–138.
Sagara, H., Sekiryu, T., Noji, H., Ogasawara, M., Sugano, Y. & Horikiri, H. (2014) Meibomian gland loss due to trabeculectomy. Japanese Journal of Ophthalmology, 58, 334–341.
Samico, G.A., Abe, R.Y., Prata, T.S., Teixeira, S.H., Paranhos, A., Jr. & Gracitelli, C.P.B. (2023) Relationship between the number of glaucoma medications, ocular surface disorder, and treatment adherence. Arq Bras Oftalmol, 87(6), e20210525.
Schirra, F., Suzuki, T., Richards, S.M., Jensen, R.V., Liu, M., Lombardi, M.J. et al. (2005) Androgen control of gene expression in the mouse meibomian gland. Investigative Ophthalmology & Visual Science, 46, 3666–3675.
Sherwood, M.B., Grierson, I., Millar, L. & Hitchings, R.A. (1989) Long‐term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology, 96, 327–335.
Shimazaki, J., Sakata, M. & Tsubota, K. (1995) Ocular surface changes and discomfort in patients with meibomian gland dysfunction. Archives of Ophthalmology, 113, 1266–1270.
Soriano, D., Ferrandez, B., Mateo, A., Polo, V. & Garcia‐Martin, E. (2021) Meibomian gland changes in open‐angle glaucoma users treated with topical medication. Optometry and Vision Science, 98, 1177–1182.
Stapleton, F., Alves, M., Bunya, V.Y., Jalbert, I., Lekhanont, K., Malet, F. et al. (2017) TFOS DEWS II epidemiology report. The Ocular Surface, 15, 334–365.
Thein, A.S., Hedengran, A., Azuara‐Blanco, A., Arita, R., Cvenkel, B., Gazzard, G. et al. (2022) Adverse effects and safety in glaucoma patients: agreement on clinical trial outcomes for reports on eye drops (ASGARD) – a Delphi consensus statement. American Journal of Ophthalmology, 241, 190–197.
Uzunosmanoglu, E., Mocan, M.C., Kocabeyoglu, S., Karakaya, J. & Irkec, M. (2016) Meibomian gland dysfunction in patients receiving long‐term glaucoma medications. Cornea, 35, 1112–1116.
Weinreb, R.N., Aung, T. & Medeiros, F.A. (2014) The pathophysiology and treatment of glaucoma: a review. JAMA, 311, 1901–1911.
Willcox, M.D., Argüeso, P., Georgiev, G.A., Holopainen, J.M., Laurie, G.W., Millar, T.J. et al. (2017) TFOS DEWS II tear film report. The Ocular Surface, 15, 366–403.
Wong, A.B.C., Wang, M.T.M., Liu, K., Prime, Z.J., Danesh‐Meyer, H.V. & Craig, J.P. (2018) Exploring topical anti‐glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye. The Ocular Surface, 16, 289–293.
Zhang, Y., Kam, W.R., Liu, Y., Chen, X. & Sullivan, D.A. (2017) Influence of pilocarpine and timolol on human meibomian gland epithelial cells. Cornea, 36, 719–724.